Cargando…

Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report

BACKGROUND: Chimeric antigen receptor T-Cell (CAR-T) therapy is an effective new treatment for hematologic malignancies. Cytokine release syndrome (CRS) and neurologic toxicity are main toxicities. CRS-induced rhabdomyolysis (RM) followed by CAR-T therapy treatment has not been previously reported....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lan, Chen, Wei, Wang, Xiao-Min, Zhang, Shu-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477680/ https://www.ncbi.nlm.nih.gov/pubmed/36159401 http://dx.doi.org/10.12998/wjcc.v10.i26.9398

Ejemplares similares

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
por: Riegler, Lara L, et al.
Publicado: (2019)

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
por: Siegler, Elizabeth L., et al.
Publicado: (2020)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
por: Zhang, Lina, et al.
Publicado: (2021)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
por: Lai, Xun, et al.
Publicado: (2020)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
por: Guo, Hanfei, et al.
Publicado: (2022)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
por: Dave, Prashil, et al.
Publicado: (2021)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia
por: Hong, Fei, et al.
Publicado: (2021)

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
por: Shima, Haruko, et al.
Publicado: (2021)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma
por: Wang, Xue, et al.
Publicado: (2022)

Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report
por: Zi, Fu Ming, et al.
Publicado: (2021)

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy
por: Nakamura, Naokazu, et al.
Publicado: (2022)

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
por: Wang, Li-Xin, et al.
Publicado: (2018)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion
por: Bottari, Gabriella, et al.
Publicado: (2020)

Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Inoue, Yu, et al.
Publicado: (2023)

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report: Erratum
Publicado: (2018)

Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective
por: Luan, Chengxin, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia
por: Shima, Haruko, et al.
Publicado: (2022)

925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome
por: Jiang, Ying, et al.
Publicado: (2022)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Cardiovascular disease and chimeric antigen receptor cellular therapy
por: Rao, Anjali, et al.
Publicado: (2022)

Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release
por: Liu, Xuan, et al.
Publicado: (2020)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors
por: Nakajima, Kyoko, et al.
Publicado: (2022)

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
por: Shin, Seungyong, et al.
Publicado: (2023)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_meu2cvjmie4u0mv8nhudgrntf5